检索
AI 对话
AI 辅写
analysis
趋势分析
编组
数据平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

Paul Y Kwo,Norman Gitlin,R Nahass,David E Bernstein,S Rojter,Eugene R Schiff,Michael Davis,Peter J Ruane,Ziad H Younes,R Kalmeijer,Monika Peeters,Oliver Lenz,Bart Fevery,G De La Rosa, Jason A Scott,Rajesh K Sinha,J Witek

Journal of Hepatology（2015）

引用 52|浏览19
暂无评分
关键词
chronic hcv genotype,sofosbuvir,simeprevir,cirrhosis,infection,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要